Utero-placental Vascularisation in Normal & Preeclamptic & Intra-uterine

Status Recruiting

Clinical Trial Summary

Introduction

Preeclampsia (PE) and intra-uterine growth restriction (IUGR) are two major pregnancy complications related to chronic utero-placental hypoperfusion. Three-dimensional power Doppler (3DPD) angiography has been used for the evaluation of utero-placental vascularisation and three vascular indices have been calculated: the vascularisation index (VI), flow index (FI) and vascularisation-FI (VFI). However, several technical endpoints hinder the clinical use of 3DPD as physical characteristics and machine settings may affect 3DPD indices, and so its clinical significance is not yet clear.

Objectives

The primary objective is to better understand the clinical significance of 3DPD indices by evaluating the relationship between these indices and placental morphometry. Secondary objectives are (i) to determine the impact of machine settings and physical characteristics on 3DPD indices, and (ii) to evaluate physio-pathological placental vascularisation patterns.

Methods and analysis

This is a prospective controlled study. We expect to include 112 women: 84 with normal pregnancies and 28 with PE and/or IUGR (based on our former cohort study on 3DPD indices for PE and/or IUGR prediction (unpublished data)). Within 72 h before planned or semi-urgent caesarean section, utero-placental 3DPD images with five different machine settings will be acquired. Placentas will be collected and examined after surgery and stereological indices (volume density, surface density, length density) calculated. The 3DPD indices (VI, FI and VFI) of the placenta and adjacent myometrium will be calculated. Correlation between Doppler and morphological indices will be evaluated by Pearson or Spearman tests. Agreement between 3DPD indices and morphological indices will be assessed by Bland and Altman plots. The impact of Doppler settings and maternal characteristics on 3DPD indices will be evaluated with a multivariate linear regression model.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02825277
Study type	Interventional
Source	Central Hospital, Nancy, France
Contact	Olivier MOREL, MD, PhD
Email	olivier.morel17@gmail.com
Status	Recruiting
Phase	N/A
Start date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03510286` - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Recruiting	`NCT03313024` - Berlin-Brandenburg Pregnancy Cohort
Active, not recruiting	`NCT04990141` - Molecular Screening Method for Preeclampsia (PREMOM)
Completed	`NCT02147626` - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia	N/A
Not yet recruiting	`NCT05999851` - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy	N/A
Recruiting	`NCT02923206` - Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis	N/A
Not yet recruiting	`NCT02541110` - Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler	N/A
Completed	`NCT02554604` - Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
Completed	`NCT02384226` - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Withdrawn	`NCT05016440` - Lisinopril for Renal Protection in Postpartum Preeclamptic Women	N/A
Completed	`NCT02854501` - Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
Terminated	`NCT02558023` - The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine	Phase 3
Recruiting	`NCT02337049` - Preeclampsia Subtypes and Surrogate Markers of CVD Risk	N/A
Recruiting	`NCT02247297` - Pancreatic Stone Protein (PSP) in Pregnant Women
Completed	`NCT02238704` - Cornell University-Micronutrient Initiative Calcium Supplementation Study	N/A
Completed	`NCT01195441` - Prediction and Prevention of Preeclampsia by First Trimester Ultrasound	N/A
Withdrawn	`NCT01179542` - The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR	N/A
Completed	`NCT00456118` - Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
Recruiting	`NCT00117546` - Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia	Phase 4
Completed	`NCT00787241` - Platelet Count Trends in Pre-eclamptic Parturients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Utero-placental Vascularisation in Normal and Preeclamptic and Intra-uterine Growth Restriction Pregnancies — EVUPA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms